Vetter milestone reached in Rankweil, Austria: 100 successful aseptic fills

Representation of the completed building with an additional floor. © Vetter Pharma International GmbH

– Successful future of the site expected
– Vetter drives the expansion of the site dynamically
– Increased process reliability through uninterruptible power supply

Vetter, a globally leading pharmaceutical service provider, has successfully completed the first 100 clinical fills of liquid and freeze-dried vials at its Austrian location in Rankweil. Vetter Development Services Austria supports the manufacturing and quality control of drug candidates for clinical trials and has been experiencing impressive growth since commissioning in 2021.

“Since the opening of our state-of-the-art clinical development site in Austria a little over three years ago, we have seen a rapid increase in customer demand. This is reflected in the successful aseptic production of the first 100 clinical batches,” says Dr. Claus Feussner, Senior Vice President Vetter Development Service. “Our two clinical manufacturing facilities in Rankweil, Austria, and Skokie, near Chicago, Illinois, have exceeded our expectations. This success speaks to both the quality of the drug candidates we produce and the reliability we offer to our customers and their patients.”

In response to growing market demand, Vetter continues to invest in the Rankweil site. This includes a 14 by 24-meter roof extension, which will add a third floor to the building. This will create more office space with individual workstations, group offices, and meeting rooms. Additionally, the pharmaceutical service provider is constructing another technical building on the west side of the area. The two-story, 3,400-square-meter building will house a technical workshop and a waste disposal center in the future. Of particular importance is the modern uninterruptible power supply (UPS) that the company is installing in the basement. This will equip the Rankweil site with an autonomous power supply. The UPS compensates for voltage fluctuations and outages that could disrupt production, thereby increasing the efficiency of the manufacturing processes. The completion of these construction projects is planned for mid-2025.

“The past years in Rankweil have been very exciting, and we look forward to following the further development of the site,” says Dr. Martin Schwab, Vice President Vetter Development Services Austria. “The growth we are seeing here is primarily due to increasing customer demand and a strong order situation, which is expected to continue into the second half of the year.” Looking ahead, Vetter aims to further increase the efficiency of clinical production in Rankweil: “Our new technologies, such as the uninterruptible power supply (UPS), as well as increasing the number of employees at the site, will help us achieve this.”